Lexaria Bioscience Corp. CEO Acquires 51,134.72 in Stock
LEXX Stock | USD 2.20 0.03 1.35% |
Slightly above 57% of Lexaria Bioscience's investor base is looking to short. The analysis of the overall investor sentiment regarding Lexaria Bioscience Corp suggests that many traders are alarmed. Lexaria Bioscience's investing sentiment can be driven by a variety of factors including economic data, Lexaria Bioscience's earnings reports, geopolitical events, and overall market trends.
Lexaria |
Lexaria Bioscience Corp. CEO Richard Christopher acquired 22,828 shares of Lexaria Bioscience stock in a transaction on Monday, December 2nd. The shares were bought at an average cost of 2.24 per share, with a total value of 51,134.72. Following the completion of the transaction, the chief executive officer now owns
Read at thelincolnianonline.com
Lexaria Bioscience Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Lexaria Bioscience can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lexaria Bioscience Fundamental Analysis
We analyze Lexaria Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexaria Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexaria Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Lexaria Bioscience is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Lexaria Bioscience Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lexaria Bioscience stock to make a market-neutral strategy. Peer analysis of Lexaria Bioscience could also be used in its relative valuation, which is a method of valuing Lexaria Bioscience by comparing valuation metrics with similar companies.
Peers
Lexaria Bioscience Related Equities
PHIO | Phio Pharmaceuticals | 26.70 | ||||
ZURA | Zura Bio | 4.39 | ||||
ZVSA | ZyVersa Therapeutics | 2.63 | ||||
REVB | Revelation Biosciences | 0.80 | ||||
IMMX | Immix Biopharma | 0.46 | ||||
CNSP | Cns Pharmaceuticals | 0.91 | ||||
ICU | LMF Acquisition | 3.40 | ||||
BDRX | Biodexa Pharmaceticals | 4.26 | ||||
RNAZ | Transcode Therapeutics | 4.79 | ||||
SONN | Sonnet Biotherapeutics | 7.69 |
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.